Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Legato Merger (LEGOU)
Foxwayne Enterprises Acquisition (FOXWU)
Gores Metropoulos II (GMIIU)
Tzp Strategies Acquisition (TZPSU)
Queen's Gambit Growth Capital (GMBTU)
Upcoming IPO
Roblox Corporation (RBLX)
Dream Finders Homes, Inc. (DFH)
Myt Netherlands (MYTE)
Primavera Capital Acquisition (PV.U)
Growth Capital Acquisition (GCACU)
Virtuoso Acquisition (VOSOU)
Patria Investments Limited (PAX)
Rlx Technology, Inc. (RLX)
European Sustainable Growth Acquisition (EUSGU)
Zim Integrated Shipping Services (ZIM)
Agrify (AGFY)
Shoals Technology Group, Inc. (SHLS)
Qualtrics International Inc. (XM)
Vinci Partners Investments Ltd. (VINP)
Ortho Clinical Diagnostics Holdings Plc (OCDX)
Priced IPO
Kuke Music Holding Limited (KUKE)
Playtika Holding Corp. (PLTK)
Driven Brands Holdings Inc. (DRVN)
Petco Health And Wellness Company, Inc. (WOOF)
Poshmark, Inc (POSH)
Affirm Holdings, Inc. (AFRM)
Motorsport Gaming US Llc (MSGM)
Qilian International Holding Group (QLI)
Cullinan Oncology, Llc (CGEM)
Gracell Biotechnologies Inc. (GRCL)
Medirom Healthcare Technologies (MRM)
Glucose Biosensor Systems Greater China (GBSG)
GBS (GBS)
908 Devices Inc. (MASS)
Virios Therapeutics (VIRI)
Midwest Holding (MDWT)
Scopus BioPharma (SCPS)
Upstart Holdings, Inc. (UPST)
BioAtla, Inc.. (BCAB)
Contextlogic Inc. (WISH)
More companies

Olema Pharmaceuticals, Inc. (OLMA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted therapies for women’s cancers. Their team has spent the past decade characterizing the structure and function of the estrogen receptor, or ER, a key driver of breast cancer in approximately 75% of patients, in order to develop more potent, oral therapies that completely inactivate this signaling pathway. Their lead product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which they believe will drive deeper, more durable responses than existing therapies. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase 4 and 6, or CDK4/6, demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. In August 2020, they initiated an ongoing Phase 1/2 dose escalation and expansion trial evaluating OP-1250 for the treatment of recurrent, locally advanced or metastatic ER-positive, or ER+, human epidermal growth factor receptor 2-negative, or HER2-, breast cancer, and expect to report initial data from this trial in the second half of 2021.
Industry
Pharmaceuticals
CEO CFO
Sean Bohen Shane Kovacs
Employees Founded
10 2007

Contacts

Address: 512 2nd Street, 4th Floor San Francisco, California 94107

Telephone: (415) 651-3316

Web page: http://www.olema.com

IPO information

Expected Date 11/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $637.8
Revenues (MM) $0
Net Income (Loss) (MM) $-14.9

Voting

What do you think will happen with the OLMA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 11
Expected offer amount (MM) $170
Realized offer amount(MM) $209
Underwriters
JP Morgan/ Jefferies/ Cowen/ Canaccord Genuity ​
CO-Managers
-

Sector: Healthcare

Tweets about $OLMA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats